This scientific publication, authored by de Feraudy et al. (2024) and published in Genome Medicine, details the outcomes of the MYOCAPTURE project (conducted from 2009 to 2018). Congenital myopathies (CM) are severe, heterogeneous genetic muscle disorders that profoundly impact patient autonomy and survival, yet a substantial proportion of patients historically lack a definitive molecular diagnosis. To resolve these diagnostic blind spots, the researchers utilized exome sequencing on a large international cohort of 310 families partially excluded for frequent genetic defects.

The study achieved a conclusive diagnosis rate of 40% (123 families) and successfully expanded the known clinical landscape of CM:

• Atypical Phenotypes: Strikingly, 44% of resolved cases were linked to pathogenic variants in known myopathy genes but presented with atypical clinical or histological signs, proving that traditional assessments often fail to predict the underlying genetic defect.

• Novel Gene Discovery: The project identified 14 new myopathy genes (such as STIM1, ORAI1, and PYROXD1) not previously associated with skeletal muscle diseases, uncovering entirely novel pathomechanisms like altered calcium homeostasis via store-operated $Ca^$ entry (SOCE).

Ultimately, the publication highlights the immense value of parallel next-generation sequencing, supplemented by clinical data and muscle biopsies, in shortening the "diagnostic odyssey" for affected families. By defining precise genetic etiologies, this work paves the way for accurate genetic counseling, optimized patient care, and targeted therapeutic strategies—including drug repurposing and gene silencing.